IR

News

[The Bio] Special Contribution (Topic: CAR-T Treatment) ①

CEO of our company, contributed a special project (Topic: CAR-T treatment) consisting of three part to commemorate the 1st anniversary of the founding of the pharmaceutical bio-specialized media "THE BIO."

 

For more details, please refer to the link below.

2024-07-03

[THE BIO] Kang Taejin, Renhaim’s CEO "We will compete with the Idiotype cancer vaccine and BAFFR CAR-T"

Renhaim Inc. is currently researching and developing the DMOAD osteoarthritis ‘RTX-V002’ and Idiotype cancer vaccine ‘RTX-V002’ using mRNA technology. In addition to these pipelines, Renhaim has in-licensed a cell-therapy (BAFFR CAR-T) from PeproMene Bio, Inc. with an exclusive right to develop, manufature, and commercialize in Korea region. We plan to conduct and complete a Phase II clinical trial for BAFFR CAR-T by 2028, then followed by NDA (new drug application) submission to the Ministry of Food and Drug Safety (MFDS).

 


 

 

For more details, please refer to the link below.

2024-04-16

[Pharm News] Renhaim Boosts Global Presence in Cancer Vaccines and First-in-class Osteoarthritis Treatment at AusBiotech Conference

Renhaim Inc. participated in AusBiotech which is the largest bio-industry conference in Australia.

Renhaim Therapeutics, a key player in the mRNA-based biotech industry, made a significant impact at AusBiotech 2023, the Australian premier biotechnology conference. The event provided a platform for Renhaim to showcase its groundbreaking mRNA-based anti-cancer vaccine and cutting-edge osteoarthritis treatment technology currently under research and development. The company leveraged this opportunity to forge valuable connections within the global biotech community.

Throughout the conference, Renhaim Inc. engaged in approximately 30 partnering meetings, fostering collaborations with multinational pharmaceutical companies, overseas biotech firms, and prominent research institutes in Australia. Notably, on November 2, 2023, during the Korean Biotech Leaping towards Innovative Technology session, Director Jason Hur presented a comprehensive pitching deck highlighting the CDP project — a mRNA-based osteoarthritis therapeutics currently under development.

Tae-Jin Kang CEO of Renhaim emphasized the strategic significance of our participation, stating that "Continuing from last year and this year, Renhaim attended the AusBiotech as a member of the Korea-Australia exchange delegation. It provided a valuable platform to demonstrate our mRNA technology and pipeline. Our discussions and partnering meetings with exceptional companies hold the promise of fruitful collaborations, contributing to the overall growth of our company.


For further insights into our participation in AusBiotech 2023, please refer to the detailed article below. Stay tuned for updates on the positive outcomes anticipated from these collaborations.



2023-11-03

[Yonhap News] Revolutionizing Disease Diagnosis and Treatment: Biotech Industry Leverages Nanotechnology

Nanotechnology, the science of manipulating matter at the atomic and molecular levels, is making remarkable progress within the biopharmaceutical field. It is increasingly being harnessed for disease diagnosis, treatment, and the delivery of therapeutics.


The forefront of nanotechnology applications in the biopharmaceutical industry is most notably seen in mRNA-based drugs and the development of vaccines utilizing lipid-based nanoparticles, specifically cationic liposomes and LNPs.


Renhaim, a leading biopharmaceutical development company, is actively engaged in projects aimed at treating osteoarthritis and creating a pancreatic cancer vaccine, both of which make use of cationic liposome technology.


Our osteoarthritis treatment strategy involves encapsulating the mRNA of a specific protein responsible for controlling cartilage tissue regeneration and alleviating pain within a nanoparticle delivery system. In parallel, the pancreatic cancer vaccine employs the loading of target antigens encoded with mRNA into the nanoparticle delivery vehicle, triggering a potent anti-cancer response. This cutting-edge approach holds promise in revolutionizing the landscape of disease treatment and prevention.




For more comprehensive insights into these developments, we invite you to follow the link below for additional details.

 

2023-09-11

[The yakup]Renhaim Inc., signed a MOU with PeproMene Bio, Inc. to develop gene & cell therapy

Renhaim Therapeutics, a leading innovator in the biotechnology sector, marked a significant milestone on June 7, 2023 by establishing a strategic partnership with PeproMene Bio, a cutting-edge cell biotech based in the United States. The primary objective of this collaboration is to expedite the progress of gene and cell therapy initiatives.

In a strategic move to amplify our expertise in this realm, Renhaim has enlisted the distinguished Dr. Larry Kwak to join our Scientific Advisory Board (SAB). Dr. Kwak, renowned for his pivotal role in developing the core technology at PeproMene Bio, brings a wealth of experience and insight to our collaborative efforts.

Dr. Larry W. Kwak currently serves as the Vice President of City of Hope, one of the largest cancer centers in the United States. His remarkable contributions to the field of medicine have earned him esteemed accolades, including being named one of TIME100’s the most influential people globally in 2010. Notably, Dr. Kwak has been honored with the Ho-Am Award in Medicine in 2016, recognizing his groundbreaking contributions that have opened new horizons in medical research.

As global interest in the cancer vaccine sector continues to rise, the addition of Dr. Larry W. Kwak to our Scientific Advisory Board is poised to catapult our endeavors in the cancer vaccine field. His role as a pioneer in the cancer vaccine field and as the developer of core technology (BAFFR-CAR T) aligns seamlessly with our commitment to advancing breakthroughs in medical innovation.

The collaboration with PeproMene Bio coupled with the expertise of Dr. Kwak, underscores our dedication to accelerating progress in therapy, ultimately contributing to the advancements in the cancer vaccine field on a global scale.




2023-06-07

[NEWS 1] Renhaim Inc. participated in GBIF 2022 and delivered corporate IR

On November 23, 2022, Renhaim Inc. participated in GBIF 2022 (Global Bio Investment Forum 2022) held at Lotte Hotel in Sogongdong, Seoul, and introduced its corporate IR (Investor Relations). Renhaim CEO Taejin Kang introduced main technologies and projects of company and revealed his aspirations to establish a new mRNA-based drug development platform. The event was attended by prominent national investors and companies.


We are thrilled to bring you the latest updates from our research and development front, where the spotlight is on the revolutionary mRNA technology. This cutting-edge technology, propelled into the limelight during the COVID-19 pandemic, is proving to be a game-changer in healthcare.
The versatility of mRNA technology has been a hope in the fight against infectious diseases. Beyond its rapid response capabilities, We are harnessing this innovative platform for groundbreaking advancements in healthcare.

Our primary focus is on leveraging mRNA technology to address the fundamental causes of osteoarthritis. We are on a mission to develop a treatment that not only slows the progression of osteoarthritis but fundamentally transforms the way we approach and manage this prevalent condition.



2022-11-23

[Hit News] CEO of Renhaim Inc. attended the Cancer Science Forum, hosted by National Cancer Center

Renhaim CEO, Tae-Jin Kang participated in the Cancer Science held at National Cancer Center on 27 May 2022.
With more than 500 concerned participants and experts from MFDS, mRNA based technology companies, and medical research, CEO Kang participated in the second panel discussing while sharing various challenges in developing mRNA cancer vaccines and stressing the importance of collaboration among industry, academia, and clinicians. In addition, CEO Kang explained about the future plan for developing mRNA based cancer vaccines through ecosystem.


2022-05-27

[The yakup] Renhaim Inc. signed a MOU with Geninus Inc. to develop a mRNA based pancreatic cancer vaccine

Exciting Collaboration Unveiled: Renhaim Inc. Partners with Geninus for Pancreatic Cancer Vaccine Development

We are thrilled to announce a groundbreaking partnership between Renhaim Inc. and Geninus, marked by the signing of a Memorandum of Understanding (MOU) on March 24, 2022. This strategic collaboration aims to spearhead the development of a mRNA-based pancreatic cancer vaccine, leveraging the cutting-edge Neoantigen Screening technology of Geninus.
Under the terms of the MOU, Renhaim Inc. will harness the unique bioinformatics capabilities of Geninus to identify antigen candidates for the mRNA pancreatic cancer vaccine. 

The collaboration stems from ongoing discussions initiated in early 2022, where Renhaim and Geninus explored the potential of developing diverse cancer vaccines. Pancreatic cancer emerged as a focal point due to its marketability and perceived likelihood of success. Recognizing the substantial potential of the technology of Geninus, both companies have embarked on a joint development journey. In August 2022, following the MOU signing, we solidified our commitment by entering into an additional joint research and development agreement, marking the commencement of a comprehensive cancer vaccine development program.

Pancreatic cancer ranked fifth in global mortality rates according to OECD standards and lacks commercially available effective treatments. Renhaim is dedicated to addressing this critical gap through the development of an mRNA-based cancer vaccine that can be seamlessly integrated into combination therapy. Our mission is to contribute significantly to the advancement of pancreatic cancer treatment and bring hope to those with this formidable challenge.

We are committed to the rigorous research and development required for this ambitious endeavor, and we look forward to making a positive impact on the lives of many individuals affected by pancreatic cancer.


2022-03-24